
EPA Draft Risk Evaluation Identifies 1,3-Butadiene As Health Hazard
The EPA's draft evaluation of 1,3-butadiene reveals its potential to cause serious health issues, including leukaemia and reduced birth weights, primarily from airborne exposure near industrial sites. The public has until February 3, 2025, to comment on the evaluation, which is under review by the SACC.
Published in December 2024. Dates, deadlines and stages may have changed since.
2 min readAI-drafted, expert reviewed

The U.S. Environmental Protection Agency (EPA) has released its draft risk evaluation for 1,3-butadiene under the Toxic Substances Control Act (TSCA). Announced on 3 December 2024, the evaluation preliminarily concludes that 1,3-butadiene poses an unreasonable risk to human health, particularly for workers and surrounding communities exposed through inhalation.
Background On 1,3-Butadiene
1,3-Butadiene is a highly flammable, colourless gas with applications in manufacturing plastics, rubber, adhesives, and fuels. It is predominantly released into the air during production and processing, making airborne exposure the primary risk factor. While minimal amounts enter land or water, general exposure can also stem from vehicle emissions, tobacco smoke, and burning wood.
Health Risks Identified
EPA's draft evaluation highlights multiple health concerns, including:
Reduced birth weights during pregnancies.Increased risks of blood and immune system disorders.Associations with leukaemia, particularly among industrial workers exposed to the chemical.
Key Findings
The EPA determined that the general public, especially those in fenceline communities near industrial facilities, face significant inhalation exposure risks. Workplace scenarios, such as maintenance activities by laboratory technicians, were identified as critical contributors to this risk. However, consumer products containing trace amounts of 1,3-butadiene are not considered a significant source of exposure.
Next Steps
The draft evaluation will undergo a 60-day public comment period, concluding on 3 February 2025. The Science Advisory Committee on Chemicals (SACC) will conduct a peer review of the draft at virtual meetings scheduled for February 4 and February 25-28, 2025. Public feedback and SACC recommendations will inform the final risk evaluation.
The EPA’s findings reinforce the need for stricter risk management strategies for 1,3-butadiene, particularly in industrial and occupational settings. Further public and expert input will shape the final evaluation and subsequent regulatory actions.
Official source
regulations.govQuestions about this change
What is the primary health risk from 1,3-butadiene?
The main risks include reduced birth weights, blood disorders, and leukaemia from inhalation exposure in industrial and community settings.
How can the public participate in the EPA’s evaluation process?
Submit comments on the draft evaluation via regulations.gov under docket EPA-HQ-OPPT-2024-0425 until February 3, 2025, or register for virtual public meetings.

Dr Steven Brennan
CEO and co-founder of Foresight, and a co-opted member of ECHA's Committee for Socio-economic Analysis. He holds a PhD in chemical engineering.
More from Dr Steven BrennanFind out what this means for your products
Foresight follows changes like this one and shows where they reach your substances, products and markets.
- TSCA reportingThe TSCA status of each substance you make in or import into the US, and when each report is due.
- Portfolio impact assessmentThe products, formulations and markets a regulatory change reaches.
- Regulatory horizon scanningAlerts scored for your organisation, most important first.
Join 3,500+ professionals staying ahead
Foresight Weekly brings the week's regulatory changes across chemicals, product safety, sustainability, ESG and EHS into one email.
Read by professionals at

